Skip to Main Content
Our Commitment to Diversity

REPRESENTATIVE EXPERIENCE

Oded Green

Venture Capital Transactions; Strategic Investments

Represented Knopp Biosciences LLC in the launch of Areteia Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with Population Health Partners, and a subsequent venture capital financing led by Bain Capital in an amount of up to US$350 million.
Represented a university in its structuring of an early-stage accelerator for life sciences companies.
Represented an early-stage venture capital fund focusing in the AI health care space in its capital raise and investment in portfolio companies.
Represented an organ regeneration biotechnology company in three rounds of venture capital investments.
Represented a non-for-profit that develops an OTC drug for the treatment of opioid overdose in its funding by a pharmaceutical company under bankruptcy.
Represented a public benefit corporation that transforms plastic waste from the developing world into socially and environmentally responsible fabric in connection with several rounds of offerings to a venture capital fund, foundations, and nonprofit organizations.
Represented an insurance company in its US$150 million investment in a fund.
Represented an organ regeneration biotechnology company in its financing led by two venture capital funds and a related license agreement with an academic institution.
Represented a company in the healthcare AI space, in its Series A round of financing.
Structured the formation and fundraise of a fund for the purchase and reconstruction of distressed real estate properties.
Represented a technology company in the railroad industry in connection with several rounds of private offerings, and a related joint venture arrangement with a public railroad company.

Mergers and Acquisitions

Represented Immunetrics Inc., a bio-simulation company, in its sale to Simulations Plus (NASDAQ: SLP).
Represented Knopp Biosciences, a drug discovery company, in the sale of its subsidiary to Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), with US$100 million closing payment (cash and stock) plus earn-out payments of up to US$1.1 billion+ scaled royalties.
Represented Megaport Limited, an Australian network-as-a-service company, in its acquisition of Innovoedge Inc., an AI multi-cloud and edge application emerging growth technology company.
Represented Reventics, Inc., a health care CDI and RCM company, in its sale to Omega Healthcare.
Represented Singapore Technologies Kinetics in its acquisition of Aethon, a developer of autonomous mobile robots for manufacturing environments, hospitals, and other commercial settings.
Represented CardiacAssist dba Tandem Life, a medical device company, in its sale to LivaNova (US$250 million).
Represented Jvion, a software company in the AI health care space, in connection with a growth equity investment of JMI.
Represented Knopp Neurosciences Inc. in its US$355 million strategic license with Biogen Idec, Inc. for Knoppā€™s ALS Drug.
Represented a university in the sale of its portfolio of software, education, internet, and technology companies.
Represented Atlantic Plywood Corporation, a wholesale supplier of hardwood plywood and panel products, in its sale to Parksite Inc.
Represented a construction software company in connection with the sale of its business.

Commercial Contracts

Represented an organ regeneration company in its licensing of technology, clinical trials, research and development, and other commercial needs.
Advised a global company in connection with its contract lifecycle management (distribution, sales, and supply).
Drafted a full set of commercial contracts for a provider of a SaaS-based online fraud detection platform and a provider of a SaaS-based automated translation platform.
Represented a video games company in its negotiations of a joint development and commercialization agreement with an education toy company.
Represented a high-tech baby gear company in the license of its technology to a global toy manufacturer (US$215 million).
Represented a technology company in the railroad industry in connection with several rounds of private offerings, and a related joint venture arrangement with a public railroad company.
Represented a developer of an OTC drug for the treatment of opioid overdose in its development, clinical testing, and production arrangements.
Represented a diagnostic company in a joint development agreement related to the development, production, and supply of molecularly imprinted nanoparticles.
Represented a company that develops RFID storage and tracking solutions for healthcare providers in connection with its commercialization and marketing agreement with a multinational pharmaceutical and life sciences company.

Israeli Related Matters

Represented TDJ Pitango Ventures, a Polish-Israeli venture capital, in its investment in Cosmose, a marketing software company.
Represented TDJ Pitango Ventures, a Polish-Israeli venture capital fund, in its investment in Neptune.ml, a developer of machine learning models.
Represented a Singapore-based transportation company in its investment in a US venture capital fund. The funds will be used for investment in Israel-based mobility automotive start-up companies.
Represented a venture capital firm focusing on ophthalmology in connection with its investment in an Israeli company (Series B round).
Represented a Chinese venture capital fund in its investment in an Israeli company that develops and supplies ceramic and metal additive manufacturing technologies and solutions.
Represented a Chinese venture capital fund in its investment in an Israeli company that develops a quick charging battery for the use with phones, electric cars, and other non-wired devices.
Represented a US company in connection with its on-going relationship with the Israeli Railroad Company.
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel